Verdiva Bio names ex-Metsera CMO Steve Marso as its new medical chief ahead of interim EVOLVE-2 data on its oral GLP-1 pill ecnoglutide.
Long-acting obesity pill developer Verdiva Bio has a new chief medical officer, and he comes from a biotech that was looking at very similar technology — …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral…
Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish…
Verdiva Bio Presents Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th…
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward…
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
